Cytosorbents (NASDAQ:CTSO) Stock Passes Above Two Hundred Day Moving Average - Time to Sell?

Cytosorbents Co. (NASDAQ:CTSO - Get Free Report) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.05 and traded as high as $1.16. Cytosorbents shares last traded at $1.13, with a volume of 109,611 shares trading hands.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on CTSO. D. Boral Capital reaffirmed a "buy" rating and set a $10.00 price objective on shares of Cytosorbents in a report on Tuesday, February 25th. StockNews.com began coverage on Cytosorbents in a research note on Tuesday. They set a "hold" rating on the stock. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $4.67.

Cytosorbents Stock Down 7.7 %

The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. The business's fifty day moving average price is $1.07 and its 200 day moving average price is $1.05. The firm has a market capitalization of $55.01 million, a PE ratio of -2.79 and a beta of 0.78.

Institutional Trading of Cytosorbents

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Avenir Corp increased its holdings in shares of Cytosorbents by 4.0% in the fourth quarter. Avenir Corp now owns 3,093,946 shares of the medical research company's stock valued at $2,815,000 after purchasing an additional 118,387 shares during the period. Raymond James Financial Inc. purchased a new position in Cytosorbents in the 4th quarter valued at $99,000. Millennium Management LLC acquired a new position in Cytosorbents in the 4th quarter valued at $30,000. Geode Capital Management LLC raised its position in Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock worth $701,000 after buying an additional 32,415 shares during the last quarter. Finally, Skylands Capital LLC lifted its stake in shares of Cytosorbents by 1.0% in the 4th quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company's stock worth $2,531,000 after acquiring an additional 26,195 shares during the period. 32.87% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.